Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TARCEVA for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where TARCEVA was used for Neoplasm malignant.

Most Reported Side Effects for TARCEVA

Side Effect Reports % Deaths Hosp.
Death 274 44.0% 274 12
Rash 81 13.0% 24 18
Diarrhoea 65 10.4% 20 24
Incorrect dose administered 48 7.7% 29 4
Nausea 31 5.0% 9 11
Malignant neoplasm progression 29 4.7% 19 5
Vomiting 25 4.0% 4 13
Disease progression 21 3.4% 9 3
Off label use 16 2.6% 9 2
Decreased appetite 15 2.4% 4 7
Dehydration 15 2.4% 1 12
Dry skin 15 2.4% 4 2
Alopecia 14 2.3% 1 1
Fatigue 13 2.1% 2 5
Dyspnoea 12 1.9% 2 8

Other Indications for TARCEVA

Lung neoplasm malignant (316) Product used for unknown indication (98) Non-small cell lung cancer (64) Lung carcinoma cell type unspecified stage 0 (24) Lung adenocarcinoma (20) Pancreatic carcinoma (19) Bronchial carcinoma (15) Tracheal cancer (7) Lung cancer metastatic (5) Lung carcinoma cell type unspecified stage iv (5)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

TARCEVA Full Profile All Neoplasm malignant Drugs TARCEVA Demographics TARCEVA Timeline